Health
Interleukin-6 inhibitors appear to be a more effective treatment for COVID-19 – News-Medical.Net
New research from Boston Medical Center found that patients experiencing severe COVID-19 symptoms had improved outcomes when administered an Interleukin-6 (IL6ri) inhibitor, sarilumab or tocilizumab, given to mediate severe systemic inflammatory responses.
New research from Boston Medical Center found that patients experiencing severe COVID-19 symptoms had improved outcomes when administered an Interleukin-6 (IL6ri) inhibitor, sarilumab or tocilizumab, given to mediate severe systemic inflammatory responses.
The treatment was more effective when administered earlier in the disease course and reduced mortality rates and the need for intubation. Published in the International Journal of Infectious Diseases, the results show Interleukin-6 inhibitors…
-
Noosa News11 hours agoMega-team of heavy horses sets world record at Good Old Days Festival
-
General14 hours agoEnglish springer spaniels Kelly and Milo helping fight dieback in Western Australia
-
General13 hours agoHomicide Squad investigating ‘suspicious’ death of 84yo woman in Sydney suburb of Melonba
-
Noosa News17 hours agoMedia adviser launches $4m malicious prosecution claim over kidnap case